Research programme: protein degrader therapeutics - Celeris Therapeutics/Merck KGaA
Alternative Names: Research programme: bifunctional protein degraders - Celeris Therapeutics/Merck KGaA; Research programme: small molecule binders - Celeris Therapeutics/Merck KGaALatest Information Update: 18 Sep 2023
At a glance
- Originator Celeris Therapeutics; Merck KGaA
- Class Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified